Clinical Trial

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn: * About the safety of pembrolizumab (the study medicine) and if people tolerate it * What happens to different doses of pembrolizumab in a person's body over time * How the cancer responds (gets smaller or goes away) to treatment
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-12-11; most recent amendment 2026-07-10.
Status change: Not Yet Recruiting → Recruiting 2026-02-17
Trial Details
NCT Number NCT07302347
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Malignant Neoplasm, Carcinoma, Merkel Cell, Lymphoma
Enrollment 20 participants
Start Date 2026-06-23
Primary Completion 2029-03-30 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-13